PubRank

K Sikora

Author PubWeight™ 109.84‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cancer survival in Britain is poorer than that of her comparable European neighbours. BMJ 1999 4.39
2 New guidelines for urgent referral of patients with cancer are waste of energy. BMJ 2000 2.66
3 Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991 2.26
4 Gene therapy for cancer. Lancet 1992 1.81
5 c-myc oncogene expression in colorectal cancer. Cancer 1987 1.60
6 Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer 1986 1.47
7 Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. N Engl J Med 1978 1.44
8 Detection of the c-myc oncogene product in testicular cancer. Br J Cancer 1985 1.40
9 A new marker for testicular cancer. Br J Cancer 1985 1.39
10 Centralize cancer services. Br J Hosp Med 1990 1.38
11 Neurological effects of recombinant human interferon. Br Med J (Clin Res Ed) 1983 1.37
12 Does interferon cure cancer? Br Med J 1980 1.34
13 Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method. Cancer Res 1992 1.33
14 Stimulation of lymphocytes from patients with coeliac disease by a subfraction of gluten. Lancet 1976 1.31
15 The increasing incidence of testicular cancer in East Anglia. Br J Cancer 1984 1.28
16 Human hybridomas from malignant gliomas. Lancet 1982 1.27
17 Second opinions for patients with cancer. BMJ 1995 1.23
18 A simultaneous flow cytometric assay for c-myc oncoprotein and DNA in nuclei from paraffin embedded material. J Immunol Methods 1985 1.21
19 Genetic prodrug activation therapy for breast cancer: A phase I clinical trial of erbB-2-directed suicide gene expression. J Clin Oncol 1999 1.13
20 A novel tumour marker related to the c-myc oncogene product. Mol Cell Probes 1987 1.11
21 Interventional genetics and cancer treatment. BMJ 1993 1.10
22 Human monoclonal antibodies to lung-cancer antigens. Br J Cancer 1981 1.10
23 Oncogenes. Lancet 1983 1.09
24 c-myc oncogene product expression and prognosis in operable breast cancer. Br J Cancer 1989 1.06
25 Partial purification of tumour-specific transplantation antigens from methylcholanthrene-induced murine sarcomas by immobilized lectins. Br J Cancer 1979 1.06
26 The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumour receptors. Br J Cancer 1990 1.05
27 Gene therapy for cancer using tumour-specific prodrug activation. Gene Ther 1994 1.04
28 The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. Br J Cancer 1986 1.01
29 Value of follow up in testicular cancer. Br Med J (Clin Res Ed) 1984 1.00
30 Coupling PPD to tumour cells enhances their antigenicity in BCG-primed mice. Nature 1978 1.00
31 The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice. Immunology 1981 1.00
32 Oncogene expression in cholangiocarcinoma and in normal hepatic development. Hum Pathol 1989 0.99
33 Localisation of metastatic carcinoma by a radiolabelled monoclonal antibody. Br J Cancer 1983 0.98
34 Monoclonal immunoglobulin rescue from a patient with chronic lymphocytic leukemia and autoimmune hemolytic anemia. Blood 1979 0.98
35 Tumour inoculation during laparoscopy. Lancet 1993 0.98
36 Conventional and complementary treatment for cancer. BMJ 1989 0.97
37 Mouse-human hybridomas. The conversion of non-secreting human B cells into Ig secretors. Curr Top Microbiol Immunol 1978 0.95
38 Age as a prognostic factor in epithelial ovarian carcinoma. Br J Obstet Gynaecol 1985 0.93
39 Recombinant interferon in advanced breast cancer. Br J Cancer 1984 0.91
40 The heterogenization of tumour cells with tuberculin. I. The coupling of tuberculin to cell surfaces using con-A as ligand. Immunology 1981 0.90
41 Interferon and cancer. Br Med J (Clin Res Ed) 1983 0.90
42 Follow-up observations on the effect of human leukocyte interferon in non-Hodgkin's lymphoma. Blood 1981 0.89
43 Human hybridomas from patients with malignant disease. Br J Cancer 1983 0.88
44 Specialist surgeons and survival in breast cancer. Breast cancer is a medical, not a surgical, disease. BMJ 1996 0.88
45 Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody. J Hepatol 1986 0.87
46 Oncoprotein stability after tumour resection. Br J Cancer 1990 0.87
47 Gastric cancer and cimetidine: does delay in diagnosis matter? Lancet 1981 0.87
48 Testicular cancer and social class in East Anglia. Br J Cancer 1984 0.87
49 Localisation of lung cancer by a radiolabelled monoclonal antibody against the c-myc oncogene product. Br J Cancer 1986 0.85
50 Monoclonal antibodies in oncology. J Clin Pathol 1982 0.84
51 RAGE-dependent regulation of calcium-binding proteins S100A8 and S100A9 in human THP-1. Exp Clin Endocrinol Diabetes 2011 0.84
52 Tumour imaging and drug targeting. Br Med Bull 1984 0.84
53 Bleomycin lung: computed tomographic observations. Br J Radiol 1985 0.84
54 Oncogenes and germ cell tumours. Int J Androl 1987 0.83
55 CAG repeat polymorphism in the DNA polymerase gamma gene in a Polish population: an association with testicular cancer risk. Ann Oncol 2005 0.83
56 A global strategy for radiotherapy: a WHO consultation. Clin Oncol (R Coll Radiol) 1999 0.83
57 Flow cytometric quantitation of the c-myc oncoprotein in archival neoplastic biopsies of the colon. Mol Cell Probes 1987 0.82
58 Cancer follow up: time for review. J R Coll Gen Pract 1985 0.82
59 Human monoclonal antibodies. Nature 1982 0.82
60 Tumour localisation by human monoclonal antibodies. Med Oncol Tumor Pharmacother 1985 0.81
61 Assessment of brain changes with registered MR before and after bone marrow transplantation for chronic myeloid leukemia. AJNR Am J Neuroradiol 1996 0.81
62 Overcoming challenges of cancer treatment programmes in developing countries: a sustainable breast cancer initiative in Ethiopia. Clin Oncol (R Coll Radiol) 2008 0.81
63 Immunoprotection by embryonal carcinoma cells for methylcholanthrene-induced murine sarcomas. Nature 1977 0.80
64 New combination chemotherapy programme for bladder cancer. Br J Urol 1989 0.80
65 c-myc oncogene expression and clinical outcome in carcinoma of the cervix. Mol Cell Probes 1989 0.80
66 Complementary and conventional cancer care: the integration of two cultures. Clin Oncol (R Coll Radiol) 1993 0.80
67 Localisation of malignant glioma by a radiolabelled human monoclonal antibody. J Neurol Neurosurg Psychiatry 1983 0.80
68 Human monoclonal antibodies to glioma cells. Br J Cancer 1981 0.80
69 Multidrug resistance and behavioural phenotype of cancer cells. Cell Biol Int 1993 0.80
70 Suppression of foreign body granuloma by recombinant interferon. Br Med J (Clin Res Ed) 1984 0.79
71 Cell-surface oligosaccharides expressed by phenotypically distinct sublines of the Dunning 3327 rat prostate cancer. Biochem Soc Trans 1990 0.79
72 The current management of testicular cancer. Br J Urol 1987 0.79
73 Expression of c-myc oncogene in coeliac disease. J Clin Pathol 1987 0.79
74 C-myc expression in cervical cancer. Lancet 1987 0.78
75 Inhibition of lymphoma hybrids by human interferon. Lancet 1980 0.78
76 Detection of lymphocytes in malignant gliomas by monoclonal antibodies. J Neurol Neurosurg Psychiatry 1983 0.78
77 Abdominal pain as a presenting symptom of male germ cell tumour. Br J Urol 1985 0.78
78 Cancer genes in gastrointestinal malignancy. Baillieres Clin Gastroenterol 1990 0.78
79 Establishment and in vivo characterization of multidrug-resistant dunning R3327 rat prostate-carcinoma cell-lines. Int J Cancer 1994 0.78
80 Human genetic therapy. Mol Aspects Med 1993 0.78
81 Thymic expression of mutated B16:A preproinsulin messenger RNA does not reverse acceleration of NOD diabetes associated with insulin 2 (thymic expressed insulin) knockout. J Autoimmun 2005 0.78
82 Localisation of glioma by human monoclonal antibody. Lancet 1982 0.77
83 Germ cell-like telomeric length homeostasis in nonseminomatous testicular germ cell tumors. Oncogene 2000 0.77
84 Combined choriocarcinoma and yolk sac tumor arising in Barrett's esophagus. Cancer 1994 0.77
85 Genetic approaches to cancer therapy. Gene Ther 1994 0.77
86 Inactivation of the retinoblastoma gene does not lead to loss of TGF-beta receptors or response to TGF-beta in breast cancer cell lines. Oncogene 1991 0.77
87 Genetic prodrug activation therapy. Mol Med Today 1997 0.77
88 New therapeutic modalities for cancer. Acta Oncol 1991 0.77
89 Biological approaches to cancer therapy. J Int Med Res 1989 0.77
90 [Ventricular topography of the diencephalic ependyma in Rattus rattus (L.)--a scanning electron microscopy study]. J Hirnforsch 1977 0.77
91 The potential of oncogene products as tumour markers. Cancer Surv 1987 0.76
92 Computed tomography of testicular tumours: distribution of abdominal lymphadenopathy. Clin Radiol 1986 0.76
93 Scanning and transmission electron microscopy of intraventricular dendrite terminals of hypothalamic cerebrospinal fluid contacting neurons in Triturus vulgaris. Z Mikrosk Anat Forsch 1979 0.76
94 Generation of a monoclonal antibody to P-glycoprotein peptides using tuberculin-PPD as a carrier. Virchows Arch 1998 0.76
95 Genetic prodrug activation therapy. Lancet 1998 0.76
96 The partial purification and characterization of GnRH-like activity from prostatic biopsy specimens and prostatic cancer cell lines. J Steroid Biochem Mol Biol 1990 0.76
97 Serum levels of c-myc and c-ras oncogene products in normal subjects and in patients with neoplastic and non neoplastic conditions. Int J Biol Markers 1988 0.76
98 Gene therapy for cancer. Eur J Cancer 1991 0.76
99 Measurement of H-2 antigen and immunogenicity of methylcholanthrene-induced murine sarcomas. Br J Cancer 1978 0.75
100 Waiting times for patients with cancer. Applying conclusions from a selected sample is dangerous. BMJ 2000 0.75
101 The cyclotron saga continues. BMJ 1990 0.75
102 A preliminary trial of a novel form of active immunotherapy in squamous cell carcinoma of the lung. Br J Cancer 1985 0.75
103 Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer. Gene Ther 1998 0.75
104 Partial mastectomy alone in early breast cancer. Br Med J (Clin Res Ed) 1985 0.75
105 National cancer centre is good idea. BMJ 1999 0.75
106 Testicular relapse after chemotherapy for malignant teratoma. Br Med J (Clin Res Ed) 1987 0.75
107 Mortality in patients with testicular cancer: report of the Anglia and Trent testicular tumour groups. Br Med J (Clin Res Ed) 1986 0.75
108 Associated clinical syndromes in a patient homozygous for HLA B27. Br Med J 1978 0.75
109 Good manners for the pharmaceutical industry. Lancet 1997 0.75
110 The cyclotron saga continues. BMJ 1991 0.75
111 Breast lumps and lymphoma. Postgrad Med J 1985 0.75
112 The independent sector and advanced radiotherapy technology. Clin Oncol (R Coll Radiol) 2010 0.75
113 Protecting bone marrow by gene therapy. Gene Ther 1995 0.75
114 Monoclonal antibodies and glioma. Prog Exp Tumor Res 1985 0.75
115 Monoclonal antibodies, malignant brain tumours and other cancers. Ir Med J 1982 0.75
116 Biomarkers--the key to the clinical development of chemopreventives. Eur J Cancer Prev 2004 0.75
117 Subcutaneous culture chamber for continuous infusion of monoclonal antibodies. Lancet 1983 0.75
118 Monoclonal antibodies in oncology. Radiother Oncol 1986 0.75
119 Scheduled and unscheduled combination chemotherapy in the treatment of squamous cell lung cancer (cyclophosphamide, adriamycin, vincristine and bleomycin, with and without cis-platinum). Anticancer Res 1983 0.75
120 Top-up payments in cancer care. Clin Oncol (R Coll Radiol) 2008 0.75
121 Medical monitoring of genetic engineering research in Cambridge--the first five years. J Soc Occup Med 1982 0.75
122 Radioimmunoscintigraphy: is it a gimmick? Br J Hosp Med 1987 0.75
123 Complementary therapies and cancer care. Complement Ther Nurs Midwifery 1996 0.75
124 Collaboration--the big C. Health Serv J 1998 0.75
125 Gene therapy in the developing world. Gene Ther 1998 0.75
126 Gene therapy for urological cancer. Br J Urol 1995 0.75
127 Gene therapy for cancer. Natl Med J India 1993 0.75
128 World health. Lancet 1998 0.75
129 Monoclonal immunoscintigraphy for the detection of primary colorectal cancers: a prospective study. Br J Surg 1986 0.75
130 The selection of monoclonal antibodies for tumour localization in patients with colorectal carcinoma. Med Oncol Tumor Pharmacother 1984 0.75
131 Cancer treatment--what's new? Practitioner 1988 0.75
132 Monoclonal antibodies from mice bearing human colorectal carcinoma xenografts. Med Oncol Tumor Pharmacother 1986 0.75
133 Late relapse in testicular teratoma after chemotherapy. Lancet 1985 0.75
134 Achievable targets for cancer? Clin Oncol (R Coll Radiol) 1998 0.75
135 Interferon and malignant disease. Br J Clin Pract 1986 0.75
136 Cancer--the dual approach. Nurs Times 1992 0.75
137 Molecular biology and the treatment of cancer. Clin Radiol 1985 0.75
138 Tumour markers. Br J Hosp Med 1994 0.75
139 [Endoscopic removal of a gastric foreign body]. Wiad Lek 1982 0.75
140 Complementary medicine and cancer treatment. Practitioner 1989 0.75
141 Juices, coffee enemas, and cancer. Lancet 1990 0.75
142 First 5 years of gene therapy for cancer. Lancet 1994 0.75
143 [Scanning electron microscopic investigations on the formation of Reissner's fiber in Rattus rattus [L.] (author's transl)]. Mikroskopie 1977 0.75
144 Cannabinoids and hCG levels in patients with testicular cancer. Lancet 1983 0.75
145 Cancer toxin genes cloned. Nature 1985 0.75
146 Rhabdomyosarcoma. Morphologic, immunohistochemical, and DNA study. Gen Diagn Pathol 1997 0.75
147 The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue. Am J Clin Oncol 1988 0.75
148 Fighting cancer into the next century. Health Serv J 1998 0.75
149 [Effect of Propotox M on the mucous membrane of the stomach in rats]. Z Gesamte Hyg 1985 0.75
150 Human monoclonal antibodies. Br Med Bull 1984 0.75
151 Pituicyte fine structure in the developing neural lobe of the rat. Dev Neurosci 1981 0.75
152 Total lymphoid irradiation preceding bone marrow transplantation for chronic myeloid leukaemia. Clin Radiol 1989 0.75
153 Preoperative radiotherapy combined with resection of squamous cell carcinoma of the mid-thoracic oesophagus. Does a histopathological malignancy grading system assess actual survival? Eur J Surg Oncol 1991 0.75
154 Palliative care and cancer trials. J Med Ethics 2003 0.75
155 Gene therapy for cancer. N Z Med J 1996 0.75
156 Can Hammersmith hospital be saved? Lancet 1994 0.75
157 Advances in the management of testicular cancer. Drugs Exp Clin Res 1986 0.75
158 Eventration of the diaphragm: an unusual cause of radiation-induced diarrhoea. Clin Oncol (R Coll Radiol) 1995 0.75
159 The treatment of essential thrombocythaemia with radioactive phosphorus. Clin Radiol 1989 0.75
160 Genes and cancer: a clinical perspective. J R Coll Physicians Lond 1987 0.75
161 [Effects of calcium excess on gastric secretion in patients with duodenal ulcer after vagotomy and pylorotomy]. Pol Przegl Chir 1970 0.75
162 Cancer genes. Practitioner 1984 0.75
163 Gene therapy--heralding a new era. Gene Ther 1994 0.75
164 Multicentre cancer trials. Lancet 1980 0.75
165 Cancer genes: their clinical potential. Clin Radiol 1986 0.75
166 Tumor-specific transplantation antigens of chemically induced tumors. Adv Pathobiol 1977 0.75
167 The characterisation of gliomas using human monoclonal antibodies. Minireview on cancer research. Exp Cell Biol 1984 0.75
168 Oncogenes. Scand J Gastroenterol Suppl 1985 0.75
169 Interstitial (Leydig) cell tumour and seminoma of the same testis. Br J Radiol 1984 0.75
170 Bladder cancer: inter-relationships between chemotherapy and radiotherapy. Br J Urol 1992 0.75
171 Comparative scanning and transmission electron microscopical investigation of the medullo-spinal cerebrospinal fluid-contacting neurons. Mikroskopie 1979 0.75
172 Cancer lottery. Nurs Stand 2001 0.75
173 A sensitive chain specific radioimmunoassay for human immunoglobulins using monoclonal antibodies. J Immunol Methods 1983 0.75
174 Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer. Acta Endocrinol (Copenh) 1989 0.75
175 Cell-cycle expression of prostatic tumour oligosaccharides analysed using dual-parameter flow cytometry. Biochem Soc Trans 1990 0.75
176 Prescription for a system. Health Serv J 1990 0.75
177 [Ventricular topography of the diencephalic ependyma in Rattus rattus (L.)--a scanning electron microscopy study]. Verh Anat Ges 1978 0.75
178 What's new? Nurs Stand 1998 0.75